华海药业（600521）公告，公司于近日收到国家药监局核准签发的琥珀酸美托洛尔缓释片和盐酸尼卡地 平注射液的《药品注册证书》。琥珀酸美托洛尔缓释片用于治疗高血压、心绞痛等，2024年国内市场销 售金额约30.66亿元。盐酸尼卡地平注射液用于手术时异常高血压的紧急处理，2024年国内市场销售金 额约6.32亿元。公司在上述产品研发项目上已投入研发费用分别约1704万元和498万元。 ...

Core Viewpoint - The report highlights the commitment of Yuan Dong Bio to sustainable development through a robust ESG (Environmental, Social, and Governance) framework, emphasizing innovation, compliance, and social responsibility in the pharmaceutical industry [1][2][3]. Group 1: Company Overview - Yuan Dong Bio is dedicated to patient-centered healthcare, focusing on innovation and quality in drug development, with a significant portion of revenue allocated to R&D, exceeding 20% [2][3]. - The company has established a comprehensive governance structure, including a board of directors and various committees to ensure effective decision-making and compliance with regulations [4][5]. Group 2: ESG Commitment - The company integrates ESG principles into its core strategy, aiming for a harmonious balance between environmental sustainability, social responsibility, and corporate governance [1][5]. - Yuan Dong Bio has implemented a three-tier ESG governance structure, comprising the board, an ESG management committee, and an execution team, to oversee and enhance its sustainability initiatives [5]. Group 3: Innovation and Development - The company has a strong focus on innovation, with over 80 ongoing projects, including 18.3% dedicated to new drug development, and has achieved significant milestones in clinical trials [3][5]. - Yuan Dong Bio has successfully launched multiple high-end pharmaceutical products, including 8 domestic first generic products and 14 active pharmaceutical ingredients that meet international standards [3][4]. Group 4: Social Responsibility - The company actively engages in community support initiatives, including healthcare assistance and educational programs, reflecting its commitment to social responsibility and public health [2][5]. - Yuan Dong Bio emphasizes employee welfare and development, recognizing its workforce as a vital asset, and has implemented various programs to support employee growth and well-being [2][5].

医药生物/化学制药 苑东生物（688513.SH） 麻醉业务持续进阶，创新与出海驱动成长 2025 年 04 月 29 日 投资评级：买入（维持） | 日期 | 2025/4/28 | | --- | --- | | 当前股价(元) | 33.59 | | 一年最高最低(元) | 62.40/28.11 | | 总市值(亿元) | 59.30 | | 流通市值(亿元) | 59.30 | | 总股本(亿股) | 1.77 | | 流通股本(亿股) | 1.77 | | 近 3 个月换手率(%) | 106.41 | 股价走势图 数据来源：聚源 -36% -24% -12% 0% 12% 24% 2024-04 2024-08 2024-12 苑东生物 沪深300 相关研究报告 《业绩表现亮眼，麻醉业务持续进阶 —公司信息更新报告》-2024.10.27 《深耕麻醉镇痛领域，积极拓展海外 市场—公司首次覆盖报告》-2024.9.24 余汝意（分析师） 刘艺（联系人） yuruyi@kysec.cn liuyi1@kysec.cn 证书编号：S0790124070022 麻醉业务持续进阶，创新与出海驱动成长，维持 ...

东吴证券股份有限公司朱国广近期对苑东生物进行研究并发布了研究报告《2024年报及2025年一季报点 评：获批新品陆续放量，国际化与创新驱动增长》，给予苑东生物买入评级。 苑东生物(688513) 投资要点 事件：公司近期发布2024年及2025年一季度财报，2024年实现营业收入13.50亿元(+20.82%，括号内为同 比，下同)，实现归母净利润2.38亿元(+5.15%)，实现扣非归母净利润1.75亿元(+10.90%)，剔除股权激励费 用影响，归母净利润同比+13.47%，扣非归母净利润同比+22.87%。25Q1单季度实现营业收入3.06亿元 (-2.97%)，实现归母净利润0.61亿元(-19.22%)，实现扣非归母净利润0.46亿元(-10.79%)，25Q1利润受股权 激励费用短期承压。 各业务板块快速增长，积极拓展海外市场：分产品来看，2024年公司化学制剂板块营收10.77亿元 (+22.25%)，原料药板块营收1.21亿元(+28.65%)，CMO/CDMO业务营收0.65亿元(+111.59%)，技术服务及 转让营收0.63亿元(-42.81%)。分地区看，国内实现收入13.24亿元(+ ...

证券研究报告·公司点评报告·化学制药 苑东生物（688513） 2024 年报及 2025 年一季报点评：获批新品 陆续放量，国际化与创新驱动增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1117 | 1350 | 1593 | 1895 | 2261 | | 同比（%） | (4.56) | 20.82 | 18.02 | 18.98 | 19.31 | | 归母净利润（百万元） | 226.57 | 238.23 | 281.30 | 335.30 | 400.75 | | 同比（%） | (8.09) | 5.15 | 18.08 | 19.20 | 19.52 | | EPS-最新摊薄（元/股） | 1.28 | 1.35 | 1.59 | 1.90 | 2.27 | | P/E（现价&最新摊薄） | 26.62 | 25.32 | 21.44 | 17.99 | 15.05 | [Table_T ...